Baser M E, Mautner V F, Ragge N K, et al. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations[J]. Neurology, 1996, 47(5):1269-1277.Baser M E, Ragge N K, Riccardi V M, et al. Phenotypic variability in monozygotic twins with neurofibromatosis 2.[J]. American Journal of Medical Genetics, 1996, 64(4):563-7.Bouzas E A, Parry D M, Eldridge R, et al. Visual impairment in patients with neurofibromatosis 2.[J]. Neurology, 1993, 43(1):622-3.Doyle K J, Shelton C. Hearing preservation in bilateral acoustic neuroma surgery.[J]. American Journal of Otology, 1993, 14(6):562.Evans D G R, Lye R, Neary W, et al. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.[J]. Journal of Neurology Neurosurgery & Psychiatry, 1999, 66(6):764-767.Gardner W J, Frazier C H. BILATERAL ACOUSTIC NEUROFIBROMAS: A CLINICAL STUDY AND FIELD SURVEY OF A FAMILY OF FIVE GENERATIONS WITH BILATERAL DEAFNESS IN THIRTY-EIGHT MEMBERS[J]. Archives of Neurology & Psychiatry, 1930, 23(2):266-302.Retrosi G, Nanni L, Ricci R, et al. Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2.[J]. Journal of Pediatric Surgery, 2009, 44(7):1458.Walter J, Kuhn S A, Brodhun M, et al. Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2[J]. Clinical Neurology & Neurosurgery, 2009, 111(5):454-9.King A, Gutmann D H. The question of familial meningiomas and schwannomas: NF2B or not to be?[J]. Neurology, 2000, 54(1):4-5.Lan K, Mautner V F. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2[J]. Human Genetics, 1996, 97(2):224.Lalwani A K, Abaza M M, Makariou E V, et al. Audiologic presentation of vestibular schwannomas in neurofibromatosis type 2[J]. Am J Otol, 1998, 19(19):352-357.Long S A, Arriaga M, Nelson R A. Acoustic neuroma volume: MRI-based calculations and clinical implications[J]. Laryngoscope, 1993, 103(10):1093.Matthies C, Samii M, Krebs S. Management of vestibular schwannomas (acoustic neuromas): radiological features in 202 cases--their value for diagnosis and their predictive importance[J]. Neurosurgery, 1997, 40(3):481-2.Mautner V F, Baser M E, Kluwe L. Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations[J]. Human Genetics, 1996, 98(2):203-6.Patronas N J, Courcoutsakis N, Bromley C M, et al. Intramedullary and Spinal Canal Tumors in Patients with Neurofibromatosis 2: MR Imaging Findings and Correlation with Genotype1[J]. Radiology, 2001, 218(2):434-442.Mautner V F, Lindenau M, Köppen J, et al. [Type 2 neurofibromatosis without acoustic neuroma].[J]. Zentralblatt Für Neurochirurgie, 1995, 56(2).Ragge N K, Baser M E, Klein J, et al. Ocular abnormalities in neurofibromatosis 2.[J]. American Journal of Ophthalmology, 1995, 120(5):634-641.Rouleau G A, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.[J]. Nature, 1993, 363(6429):515-21.Kuo Y H, Roos D, Brophy B P. Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2.[J]. Journal of Clinical Neuroscience Official Journal of the Neurosurgical Society of Australasia, 2008, 15(7):744-748.Welling D B, Guida M, Goll F, et al. Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas[J]. Human Genetics, 1996, 98(2):189-93.Rouleau G A, Wertelecki W, Haines J L, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22[J]. Nature, 1987, 329(6136):246.Ruttledge M H, Andermann A A, Phelan C M, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease[J]. American Journal of Human Genetics, 1996, 59(2):331.3Rd S W, Brackmann D E, Hitselberger W. Middle fossa approach for hearing preservation with acoustic neuromas[J]. American Journal of Otology, 1997, 18(5):596.Slattery, Iii W H, Brackmann, et al. Hearing Preservation and Restoration in CPA Tumor Surgery[J]. Neurosurgery Quarterly, 1997, 7(3):169-182.Nagato T, Katada A, Yoshizaki T, et al. Laryngeal plexiform schwannoma as first symptom in a patient with neurofibromatosis type 2.[J]. Clinical Neurology & Neurosurgery, 2010, 112(6):505-508.Altuna X, Lopez J P, Yu M A, et al. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.[J]. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2011, 32(1):163-70.Ammoun S, Cunliffe C H, Allen J C, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.[J]. Neuro-oncology, 2010, 12(8):834.Ammoun S, Flaiz C, Ristic N, et al. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma[J]. Cancer Research, 2008, 68(13):5236-45.Ammoun S, Schmid M C, Triner J, et al. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2[J]. Neuro-Oncology, 2011, 13(7):759-766.Bush M L, Oblinger J, Brendel V, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas[J].  2011, 13(9):983-999.Fernandezvalle C, Tang Y, Ricard J, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology[J]. Nature Genetics, 2002, 31(4):354-62.James M F, Han S, Polizzano C, et al. NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth[J]. Molecular & Cellular Biology, 2009, 29(15):4250.Kaempchen K, Mielke K, Utermark T, et al. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells.[J]. Human Molecular Genetics, 2003, 12(11):1211-21.Lallemand D, Curto M, Saotome I, et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions[J]. Genes & Development, 2003, 17(9):1090-100.Lee T X, Packer M D, Huang J, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.[J]. European Journal of Cancer, 2009, 45(9):1709-1720.Morrison H, Sherman L S, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44[J]. Genes & Development, 2001, 15(8):968-80.Li W, You L, Cooper J, et al. Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus[J]. Cell, 2010, 140(4):477-490.Mautner V F, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas leading to improved hearing in neurofibromatosis type 2 patients[J]. Aktuelle Neurologie, 2009, 36(S 02):14-18.Plotkin S R, Stemmerrachamimov A O, Ii F G B, et al. Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2[J]. New England Journal of Medicine, 2009, 361(4):358.Wang Z, Lu Y, Tang J, et al. The phosphorylation status of merlin in sporadic vestibular Schwannomas.[J]. Molecular and Cellular Biochemistry, 2009, 324(1):201-206.Yang C, Asthagiri A R, Iyer R R, et al. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.[J]. Proc Natl Acad Sci U S A, 2011, 108(12):4980.Zhou L, Ercolano E, Ammoun S, et al. Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways[J]. Neoplasia, 2011, 13(12):1101-1112.